Clinical trial · Observational
Cell Free DNA and Its Integrity Using ALU Sequences as a Biomarker for Diagnosis of Breast Cancer
The Role of Circulating Cell-free DNA and Its Integrity Using ALU (247/115) bp Sequences as a Biomarker for Diagnosis of Breast Cancer
NCT03474016CI-TRIAL-00033035unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer (BC) is the most common cancer in women worldwide, and is the leading cause of death from cancer among women globally. Mammography is the standard method for early detection of BC in many countries, with over 1.3 million annually new diagnosed cases.In Egypt, breast cancer is the most common cancer in females accounting for 38.8% of all female cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Patients with early breast cancer(30)
- interventionNames
- Diagnostic Test: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
- label
- Patients with advanced breast cancer(30)
- interventionNames
- Diagnostic Test: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
- label
- Patients with benign breast diseases(20)
- interventionNames
- Diagnostic Test: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
- label
- Apparently healthy females as a control group(36)
- interventionNames
- Diagnostic Test: Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 19 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * All patients enrolled before initiation of any treatment. Exclusion Criteria: * Any other malignant or benign tumors. * Active inflammatory or autoimmune diseases. * Renal or liver diseases.
References
Publications (0)
Data not yet available
No reference posted for this study.